Literature DB >> 21966548

Immunohistochemical staining of slit2 in primary and metastatic prostatic adenocarcinoma.

Tanner L Bartholow1, Michael J Becich, Uma R Chandran, Anil V Parwani.   

Abstract

BACKGROUND: Conflicting roles for Slit2, a protein involved in mediating the processes of cell migration and chemotactic response, have been previously described in prostate cancer. Here we use immunohistochemistry to evaluate the expression of Slit2 in normal donor prostate (NDP), benign prostatic hyperplasia (BPH), high-grade prostatic intraepithelial neoplasia (HGPIN), normal tissue adjacent to prostatic adenocarcinoma (NAC), primary prostatic adenocarcinoma (PCa), and metastatic prostatic adenocarcinoma (Mets).
METHODS: Tissue microarrays were immunostained for Slit2. The staining intensities were quantified using automated image analysis software. The data was statistically analyzed using one-way analysis of variance with subsequent Tukey tests for multiple comparisons or a nonparametric equivalent. Eleven cases of NDP, 35 cases of NAC, 15 cases of BPH, 35 cases of HGPIN, 106 cases of PCa, and 37 cases of Mets were analyzed.
RESULTS: Specimens of PCa and HGPIN had the highest absolute staining for Slit2. Significant differences were seen between PCa and NDP (P < .05), PCa and NAC (P < .05), HGPIN and NDP (P < .05), and HGPIN and NAC (P < .05). Whereas the average Mets staining was not significantly different from NDP or NAC, several individual Mets cases featured intense staining.
CONCLUSIONS: To our knowledge, this represents the first study comparing the immunohistochemical profiles of Slit2 in PCa and Mets to specimens of HGPIN, BPH, NDP, and NAC. These findings suggest that Slit2 expression can be increased in HGPIN, PCa, and Mets, making it a potentially important biomarker for prostate cancer.

Entities:  

Year:  2011        PMID: 21966548      PMCID: PMC3162306          DOI: 10.1593/tlo.11151

Source DB:  PubMed          Journal:  Transl Oncol        ISSN: 1936-5233            Impact factor:   4.243


  40 in total

1.  Quantification of expression of netrins, slits and their receptors in human prostate tumors.

Authors:  Alain Latil; Laurent Chêne; Béatrix Cochant-Priollet; Philippe Mangin; Georges Fournier; Philippe Berthon; Olivier Cussenot
Journal:  Int J Cancer       Date:  2003-01-20       Impact factor: 7.396

2.  cAMP-induced switching in turning direction of nerve growth cones.

Authors:  H J Song; G L Ming; M M Poo
Journal:  Nature       Date:  1997-07-17       Impact factor: 49.962

3.  SLIT2, a human homologue of the Drosophila Slit2 gene, has tumor suppressor activity and is frequently inactivated in lung and breast cancers.

Authors:  Ashraf Dallol; Nancy Fernandes Da Silva; Paolo Viacava; John D Minna; Ivan Bieche; Eamonn R Maher; Farida Latif
Journal:  Cancer Res       Date:  2002-10-15       Impact factor: 12.701

Review 4.  Slit2/Robo1 signaling in glioma migration and invasion.

Authors:  Yun Xu; Wen-Liang Li; Li Fu; Feng Gu; Yong-Jie Ma
Journal:  Neurosci Bull       Date:  2010-12       Impact factor: 5.203

5.  Angiocrine factors modulate tumor proliferation and motility through EphA2 repression of Slit2 tumor suppressor function in endothelium.

Authors:  Dana M Brantley-Sieders; Charlene M Dunaway; Meghana Rao; Sarah Short; Yoonha Hwang; Yandong Gao; Deyu Li; Aixiang Jiang; Yu Shyr; Jane Y Wu; Jin Chen
Journal:  Cancer Res       Date:  2010-12-08       Impact factor: 12.701

6.  Frequent epigenetic inactivation of the SLIT2 gene in gliomas.

Authors:  Ashraf Dallol; Dietmar Krex; Luke Hesson; Charis Eng; Eamonn R Maher; Farida Latif
Journal:  Oncogene       Date:  2003-07-17       Impact factor: 9.867

7.  Induction of tumor angiogenesis by Slit-Robo signaling and inhibition of cancer growth by blocking Robo activity.

Authors:  Biao Wang; Yang Xiao; Bei Bei Ding; Na Zhang; Xiao bin Yuan; Lü Gui; Kai Xian Qian; Shumin Duan; Zhengjun Chen; Yi Rao; Jian Guo Geng
Journal:  Cancer Cell       Date:  2003-07       Impact factor: 31.743

8.  Frequent epigenetic inactivation of the SLIT2 gene in chronic and acute lymphocytic leukemia.

Authors:  Thomas L Dunwell; Rachel E Dickinson; Tatjana Stankovic; Ashraf Dallol; Victoria Weston; Belinda Austen; Daniel Catchpoole; Eamonn R Maher; Farida Latif
Journal:  Epigenetics       Date:  2009-05-01       Impact factor: 4.528

9.  Using image analysis as a tool for assessment of prognostic and predictive biomarkers for breast cancer: How reliable is it?

Authors:  Mark C Lloyd; Pushpa Allam-Nandyala; Chetna N Purohit; Nancy Burke; Domenico Coppola; Marilyn M Bui
Journal:  J Pathol Inform       Date:  2010-12-23

10.  SLIT2 promoter methylation analysis in neuroblastoma, Wilms' tumour and renal cell carcinoma.

Authors:  D Astuti; N F Da Silva; A Dallol; D Gentle; T Martinsson; P Kogner; R Grundy; T Kishida; M Yao; F Latif; E R Maher
Journal:  Br J Cancer       Date:  2004-01-26       Impact factor: 7.640

View more
  1 in total

1.  Differential gene expression profiling of matched primary renal cell carcinoma and metastases reveals upregulation of extracellular matrix genes.

Authors:  T H Ho; D J Serie; M Parasramka; J C Cheville; B M Bot; W Tan; L Wang; R W Joseph; T Hilton; B C Leibovich; A S Parker; J E Eckel-Passow
Journal:  Ann Oncol       Date:  2017-03-01       Impact factor: 32.976

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.